Acne medication market size worldwide 2022 and 2032

In 2022, the acne treatment market was valued at some ten billion U.S. dollars. However, until 2032 it is expected to increase to over 17 billion U.S. dollars.Acne and skin care Acne is a skin condition caused by a clogging of hair follicles with dead skin or oils. This condition is also knows as acne vulgaris. Acne is a very common medical condition and a majority of the world’s population has been affected by acne in their life. There are a variety of treatment options and skin care products used for acne. Despite acne being a common skin condition, recent estimates indicate that acne treatment products contributed a small amount to the overall sales of skin care products globally. U.S. acne treatment market In the U.S., Neutrogena had the highest share of sales for acne medications and treatments in the past. In the U.S. some acne products require a prescription and some do not. Among prescription oral acne drugs, Oracea has a leading position, while among topical prescription acne drugs, Epiduo is one of the dominating products.

2022年，痤疮治疗市场估值已达到约一百亿美元。然而，预计到2032年，其规模将增长至超过一百七十亿美元。痤疮，亦称为寻常痤疮，是由死皮或油脂堵塞毛囊所致的皮肤状况。痤疮是一种极为普遍的医学状况，世界上大多数人口在其一生中均曾受到痤疮的影响。针对痤疮的治疗方案及护肤产品种类繁多。尽管痤疮是一种常见的皮肤疾病，但最新的估计表明，痤疮治疗产品在全球护肤产品总体销售额中仅占一小部分。美国痤疮治疗市场在美国，Neutrogena曾拥有痤疮药物及治疗产品的最高市场份额。在美国，部分痤疮产品需要处方，而部分则无需。在处方口服痤疮药物中，Oracea占据领先地位，而在处方外用痤疮药物中，Epiduo则是主导产品之一。